. Author manuscript; available in PMC: 2024 Feb 1.

Published in final edited form as: JAMA Cardiol. 2023 Aug 1;8(8):721–731. doi: 10.1001/jamacardio.2023.1469

Table 1:

a. nsBAV discovery cohort and replication cohorts, N= 938 BAV cases.

Cohort	N	Center	City, Country	BAV cases, n (families)	Sex, % males (n)	Age, years, mean±SD
Discovery cohort	N = 69, Famillial cases	APHP-Hôpital Européen Georges Pompidou	Paris, France	46 (18)	77.4% (127)	51 (±15.5)
Discovery cohort	N = 69, Famillial cases	Hadassah Medical Center	Jerusalem, Israel	23 (11)	69% (40)	44.8 ±18.8
Replication cohort I	N= 417 Cases*	MIBAVA-Leducq	Europe*, Canada, United States	195¹	-	52.2 ±11.8
		APHP-Hôpital Européen Georges Pompidou	Paris, France	164	65.2% (30)	39 (± 16.5)
		Hadassah Medical Center	Jerusalem, Israel	58	73.9% (17)	40 ±22.7
	N = 62,874 Controls	Genome Aggregation Database	Mixed	-	-	-
Replication cohort II	N = 452 Cases	Mass General Brigham Hospital	Boston, MA, United States	452	74.3% (336)	54.4 ±11.8
Replication cohort II	N = 1834 Controls	The database of Genotypes and Phenotypes	Framingham Heart Study, United States	-	54.4% (713)	-